Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis

OBJECTIVE: The use of tenofovir (TDF) and entecavir (ETV) in patients with chronic hepatitis B (CHB) has led to a decrease in the incidence of hepatocellular carcinoma (HCC) and liver-related events. However, whether there is a difference between the two agents in the extent of improving such outcom...

Full description

Saved in:
Bibliographic Details
Published in:Gut
Main Authors: Lee, Sung Won, Kwon, Jung Hyun, Lee, Hae Lim, Yoo, Sun Hong, Nam, Hee Chul, Sung, Pil Soo, Nam, Soon Woo, Bae, Si Hyun, Choi, Jong Young, Yoon, Seung Kew, Han, Nam Ik, Jang, Jeong Won
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2020
Subjects:
Hepatology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7306978/
https://ncbi.nlm.nih.gov/pubmed/31672838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2019-318947
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items